CHIMERIX INC. - COMMON STOCK

Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs

08 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Chimerix to Present at Wedbush PacGrow Healthcare Conference

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022

01 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

24 Jun 2022 10:06:16 By Nasdaq GlobeNewswire

Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

23 Jun 2022 09:15:16 By Nasdaq GlobeNewswire

Chimerix to Present at Jefferies Global Healthcare Conference

01 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Chimerix to Present at H.C. Wainwright Global Investment Conference

17 May 2022 16:15:00 By Nasdaq GlobeNewswire

Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

16 May 2022 06:30:00 By Nasdaq GlobeNewswire

Chimerix to Participate in Maxim Group Panel Discussion

12 May 2022 16:15:00 By Nasdaq GlobeNewswire

Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022

09 May 2022 07:00:01 By Nasdaq GlobeNewswire

Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

21 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update

01 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research

24 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Chimerix to Present at B. Riley Virtual Oncology Conference

20 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

18 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

03 Jan 2022 16:45:00 By Nasdaq GlobeNewswire

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting

19 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Chimerix to Present at Jefferies London Healthcare Conference

12 Nov 2021 08:00:01 By Nasdaq GlobeNewswire